Silence Therapeutics plc (SLN)

21.60 -0.02 (-0.07%) At close: 04:00PM EDT

Silence Therapeutics plc

72 Hammersmith Road
London W14 8TH
United Kingdom
44 20 3457 6900
https://www.silence-therapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 109

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Craig A. Tooman M.B.A.	President, CEO & Executive Director	1.47M	N/A	1965
Ms. Rhonda L. Hellums	CFO & Secretary	894.31k	N/A	1973
Dr. Steven J. Romano M.D.	Head of Research & Development	653.21k	N/A	1959
Dr. Marie Wikstrom Lindholm Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Gem Gokmen Hopkins	Head of IR & Corporate Communications	N/A	N/A	N/A
Dr. Barbara A. Ruskin J.D., Ph.D.	Senior VP and Chief Intellectual Property & Innovation Officer	N/A	N/A	1961
Dr. Eric Floyd M.B.A., M.S., Ph.D.	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	1963
Mr. J.P. Gabriel	Chief Technical Operations Officer	N/A	N/A	N/A
Mr. Curtis Rambaran M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Corporate governance

Silence Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.